Wealthfront Advisers LLC Has $2.70 Million Stake in IQVIA Holdings Inc. $IQV

Wealthfront Advisers LLC lifted its position in IQVIA Holdings Inc. (NYSE:IQV) by 72.5% in the fourth quarter, HoldingsChannel.com reports. The firm owned 11,989 shares of the medical research company’s stock after acquiring an additional 5,040 shares during the period. Wealthfront Advisers LLC’s holdings in IQVIA were worth $2,702,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also modified their holdings of the company. Ameliora Wealth Management Ltd. bought a new stake in IQVIA in the fourth quarter valued at $25,000. Physician Wealth Advisors Inc. grew its position in IQVIA by 1,340.0% in the third quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company’s stock valued at $27,000 after acquiring an additional 134 shares during the period. Westside Investment Management Inc. grew its position in IQVIA by 219.6% in the third quarter. Westside Investment Management Inc. now owns 147 shares of the medical research company’s stock valued at $30,000 after acquiring an additional 101 shares during the period. Measured Wealth Private Client Group LLC bought a new stake in IQVIA in the third quarter valued at $30,000. Finally, Atlantic Union Bankshares Corp bought a new stake in IQVIA in the third quarter valued at $36,000. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

IQV has been the topic of a number of analyst reports. JPMorgan Chase & Co. lowered their price target on IQVIA from $255.00 to $225.00 and set an “overweight” rating on the stock in a research report on Friday, February 6th. UBS Group decreased their target price on IQVIA from $280.00 to $240.00 and set a “buy” rating on the stock in a report on Friday, February 6th. Morgan Stanley set a $240.00 target price on IQVIA in a report on Wednesday, February 11th. Royal Bank Of Canada began coverage on IQVIA in a report on Tuesday, March 3rd. They set an “outperform” rating and a $221.00 target price on the stock. Finally, Truist Financial decreased their target price on IQVIA from $290.00 to $245.00 and set a “buy” rating on the stock in a report on Thursday, February 19th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat, IQVIA currently has a consensus rating of “Buy” and an average target price of $226.63.

IQVIA Price Performance

IQVIA stock opened at $157.73 on Friday. The business’s 50-day simple moving average is $169.36 and its 200 day simple moving average is $201.57. The stock has a market cap of $26.77 billion, a price-to-earnings ratio of 20.07, a P/E/G ratio of 1.58 and a beta of 1.18. IQVIA Holdings Inc. has a 12-month low of $134.65 and a 12-month high of $247.04. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.09.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Thursday, February 5th. The medical research company reported $3.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.40 by $0.02. The business had revenue of $4.36 billion for the quarter, compared to analysts’ expectations of $4.24 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.34%.The firm’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same quarter last year, the business earned $3.12 earnings per share. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. As a group, research analysts anticipate that IQVIA Holdings Inc. will post 11.5 earnings per share for the current year.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real?world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real?world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.